GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

Friday, December 2, 2016

CDSCO Informs Abbott, Glaxo and Pfizer of Outcome of Review of FDC Data

Image result for cdsco

The Central Drugs Standard Control Organization (CDSCO) has contacted 283 drugmakers including Abbott, GlaxoSmithKline and Pfizer about its review of their fixed-dose combination (FDC) products. The review looked at the safety and efficacy of FDCs sold without approval at the national level.
CDSCO and a FDC-focused expert committee conducted the review to assess whether applications filed by companies supported the continued sale of certain products, despite them never having been approved by the Drug Controller General of India (DCGI). In each case, the reviewers have issued either a no objection certificate for the continued manufacturing and marketing of the FDC, a show cause notice or a letter requesting the running of a Phase IV trial.
The notice released publicly by CDSCO lists the companies that have been the subject of review and how many letters they have received, but lacks details of the FDCs assessed and the conclusions reached by the regulator. The notice illustrates the scale of the task undertaken by CDSCO. With the review covering 283 companies, some of which are subject to many assessments, CDSCO sent out close to 1,000 letters detailing its findings.
Publication of the letters moves CDSCO a step closer to its long-standing goal of rationalizing the FDC market in India. In the past, companies introduced FDCs without first securing approval from DCGI. This led to FDCs with questionable safety and therapeutic rationale being available in India. CDSCO wrote to manufacturers in January 2013 seeking data to support the continued use of their FDCs. The letters sent out this week are the result of reviews of data received following that request.
Downloads: CDSCO Alert, Other (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images posted here are belongs to respective to Authority / owners of firm.


Post a Comment

Related Posts Plugin for WordPress, Blogger...


Popular Posts


Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner



Subscribe via email for free


Enter your email address:

Delivered by FeedBurner

Contact Form


Email *

Message *

Menu :
Powered by Blogger.



    Related Posts Plugin for WordPress, Blogger...


    2016 (37) 2017 (85) 2018 (9) 211 CFR (1) 211.63 (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (70) FDA Guide (18) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (39) MAR17 (13) Mar18 (7) May17 (10) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (43) WHO (6) zika (1)


    Theme Support